HRP20090646T1 - Uporaba 5'-metiltioadenozina (mta) kod prevencije i/ili liječenja autoimunih bolesti i/ili odbacivanje transplantata - Google Patents
Uporaba 5'-metiltioadenozina (mta) kod prevencije i/ili liječenja autoimunih bolesti i/ili odbacivanje transplantata Download PDFInfo
- Publication number
- HRP20090646T1 HRP20090646T1 HR20090646T HRP20090646T HRP20090646T1 HR P20090646 T1 HRP20090646 T1 HR P20090646T1 HR 20090646 T HR20090646 T HR 20090646T HR P20090646 T HRP20090646 T HR P20090646T HR P20090646 T1 HRP20090646 T1 HR P20090646T1
- Authority
- HR
- Croatia
- Prior art keywords
- use according
- treatment
- mta
- prevention
- medication
- Prior art date
Links
- WUUGFSXJNOTRMR-IOSLPCCCSA-N 5'-S-methyl-5'-thioadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 WUUGFSXJNOTRMR-IOSLPCCCSA-N 0.000 title claims abstract 7
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract 6
- 230000002265 prevention Effects 0.000 title claims abstract 5
- 206010052779 Transplant rejections Diseases 0.000 title claims abstract 4
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract 9
- 229940002612 prodrug Drugs 0.000 claims abstract 3
- 239000000651 prodrug Substances 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 229940079593 drug Drugs 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 230000001934 delay Effects 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000012620 biological material Substances 0.000 claims 1
- 238000002659 cell therapy Methods 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 210000003414 extremity Anatomy 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000009168 stem cell therapy Methods 0.000 claims 1
- 238000009580 stem-cell therapy Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000002123 temporal effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Abstract
Uporaba 5'-metiltioadenozina (MTA), njegovih farmaceutski prihvatljivih soli i/ili prolijekova, gdje su navedeni prolijekovi esteri ili amidi MTA koji, nakon što su primijenjeni na osobi, daju MTA, direktno ili indirektno, navedenoj osobi, za pripravu medikamenta za (i) prevenciju i/ili liječenje autoimune bolesti ili za (ii) prevenciju i/ili liječenje odbacivanja transplantata. Patent sadrži još 6 patentnih zahtjeva.
Claims (7)
1. Uporaba 5'-metiltioadenozina (MTA), njegovih farmaceutski prihvatljivih soli i/ili prolijekova, gdje su navedeni prolijekovi esteri ili amidi MTA koji, nakon što su primijenjeni na osobi, daju MTA, direktno ili indirektno, navedenoj osobi, za pripravu medikamenta za (i) prevenciju i/ili liječenje autoimune bolesti ili za (ii) prevenciju i/ili liječenje odbacivanja transplantata.
2. Uporaba prema zahtjevu 1, gdje je navedena autoimuna bolest multipla skleroza (MS), Chronova bolest, reumatoidni artritis, dijabetes melitus tipa 1, psorijaza, lupus, ulcerozni kolitis, vitiligo, celijakija, vaskulitis, dermatomiozitis, polimiozitis, tirozitis (Hashimoto, Graves), mijastenija gravis, Guillain-Barrov sindrom, uveitis, lihen planus, temporalni artritis, sarkoidoza, suhi sindrom (Sjöegren), bronhijalna astma, plikovnjača, ankilozantni spondilitis, sklerodermija, fibromialgija ili reumatska groznica.
3. Uporaba prema zahtjevu 1, gdje je navedena autoimuna bolest multipla skleroza (MS).
4. Uporaba prema zahtjevu 3, gdje navedeni medikament odgađa nastup početka kod osobe koja boluje od MS-e ili odgađa progresiju MS-e (progresivna faza) kod osobe koja boluje od MS-e.
5. Uporaba prema zahtjevu 1, gdje se navedeni transplantat odabire iz bubrega, jetre, srca, crijeva, hematopoetske i leđne moždine, kože, uda, rožnice, gušterače, matične stanice i stanične terapije, i presadaka ili bioloških materijala.
6. Uporaba prema zahtjevu 1, gdje je navedeni medikament primjeren za oralnu, subkutanu, intraperitonealnu ili intravenoznu primjenu.
7. Uporaba prema zahtjevu 1, gdje se navedeni medikament primjenjuje u kombinaciji s drugim dodatnim lijekovima koji su korisni u primjeni i/ili liječenju autoimunih bolesti ili odbacivanju transplantata.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/ES2005/000139 WO2006097547A1 (es) | 2005-03-17 | 2005-03-17 | Empleo de 5'-metiltioadenosina (mta) en la prevención y/o tratamiento de enfermedades autoinmunes y/o rechazo de transplantes |
| HR20090646 | 2009-12-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20090646T1 true HRP20090646T1 (hr) | 2010-01-31 |
Family
ID=36991307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090646T HRP20090646T1 (hr) | 2005-03-17 | 2009-12-04 | Uporaba 5'-metiltioadenozina (mta) kod prevencije i/ili liječenja autoimunih bolesti i/ili odbacivanje transplantata |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7820637B2 (hr) |
| EP (1) | EP1891961B1 (hr) |
| JP (1) | JP2008533107A (hr) |
| CN (1) | CN101141970A (hr) |
| AT (1) | ATE442854T1 (hr) |
| AU (1) | AU2005329287B2 (hr) |
| BR (1) | BRPI0520129A2 (hr) |
| CA (1) | CA2601557A1 (hr) |
| CY (1) | CY1109539T1 (hr) |
| DE (1) | DE602005016729D1 (hr) |
| DK (1) | DK1891961T3 (hr) |
| ES (1) | ES2334924T3 (hr) |
| HR (1) | HRP20090646T1 (hr) |
| MX (1) | MX2007011327A (hr) |
| PL (1) | PL1891961T3 (hr) |
| PT (1) | PT1891961E (hr) |
| RS (1) | RS51122B (hr) |
| SI (1) | SI1891961T1 (hr) |
| WO (1) | WO2006097547A1 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2329327B1 (es) | 2008-03-19 | 2010-09-17 | Proyecto De Biomedicina Cima, S.L. | Combinaciones sinergicas de 5'-metiltioadenosina. |
| CN102573854A (zh) * | 2009-06-11 | 2012-07-11 | 普罗耶克托生物医学Cima有限公司 | 5’-甲硫腺苷的神经保护特性 |
| WO2011054990A2 (es) * | 2009-11-05 | 2011-05-12 | Proyecto De Biomedicina Cima, S.L. | Composiciones para la inhibición y/o bloqueo de la transición epitelial-mesenquimal |
| JP5801572B2 (ja) * | 2011-03-03 | 2015-10-28 | シーシーアイ株式会社 | ＰＰＡＲγ活性化剤 |
| CN105153042B (zh) * | 2015-07-17 | 2017-11-24 | 四川大学 | 一种化合物及其在制备治疗可卡因成瘾的药物中的用途 |
| WO2020206289A1 (en) * | 2019-04-05 | 2020-10-08 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 |
| WO2020206299A1 (en) * | 2019-04-05 | 2020-10-08 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 |
| CN114515294A (zh) | 2022-02-25 | 2022-05-20 | 浙江中医药大学 | 5’-甲基硫代腺苷在制备肥胖抑制药物或保健品中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1193529B (it) * | 1980-04-22 | 1988-07-08 | Bioresearch Srl | Derivati adenosinici ad attivita' antinfiammatoria ed analgesica e composizioni terapeutiche che li contengono come principio attivo |
| IT1227049B (it) * | 1988-07-29 | 1991-03-14 | Bioresearch Spa | Impiego di derivati adenosinici per la preparazione di composizioni farmaceutiche aventi attivita' immunostimolante. |
| ATE271063T1 (de) * | 1996-10-16 | 2004-07-15 | Icn Pharmaceuticals | Purin-l-nukleoside, deren analoga und verwendungen |
| CA2306811A1 (en) * | 1997-10-14 | 1999-04-22 | Yoshiyuki Aoki | Piperazine compounds and medicinal use thereof |
| TW466112B (en) * | 1998-04-14 | 2001-12-01 | Lilly Co Eli | Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same |
| JP2001072660A (ja) * | 1999-09-08 | 2001-03-21 | Welfide Corp | ＴＮＦ−α産生抑制剤および／またはＩＬ−１０産生促進剤 |
| CZ20022413A3 (cs) * | 2000-01-31 | 2003-08-13 | Pfizer Products Inc. | Pyrimidinkarboxamidy užitečné jako inhibitory isozymů PDE4 |
| AU2001241067A1 (en) * | 2000-03-09 | 2001-09-17 | Ono Pharmaceutical Co. Ltd. | Omega-substituted phenyl-prostaglandin e-alcohols, process for producing the same and drugs containing the same as the active ingredient |
| WO2003028712A2 (en) * | 2001-09-28 | 2003-04-10 | Universite Libre De Bruxelles | Purinergic and pyrimidinergic receptor agonists for the treatment of activated cd4+ t lymphocyte-mediated immune diseases |
| DE10207843A1 (de) * | 2002-02-15 | 2003-09-04 | Schering Ag | Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen |
| IL148736A0 (en) * | 2002-03-18 | 2002-09-12 | Pharmos Corp | Dexanabinol and dexanabinol analogs which regulate inflammation related genes |
-
2005
- 2005-03-17 ES ES05728461T patent/ES2334924T3/es active Active
- 2005-03-17 RS RSP-2009/0549A patent/RS51122B/sr unknown
- 2005-03-17 MX MX2007011327A patent/MX2007011327A/es active IP Right Grant
- 2005-03-17 SI SI200530844T patent/SI1891961T1/sl unknown
- 2005-03-17 PT PT05728461T patent/PT1891961E/pt unknown
- 2005-03-17 CA CA002601557A patent/CA2601557A1/en not_active Abandoned
- 2005-03-17 EP EP05728461A patent/EP1891961B1/en active Active
- 2005-03-17 AU AU2005329287A patent/AU2005329287B2/en not_active Ceased
- 2005-03-17 DE DE602005016729T patent/DE602005016729D1/de active Active
- 2005-03-17 PL PL05728461T patent/PL1891961T3/pl unknown
- 2005-03-17 CN CNA2005800491430A patent/CN101141970A/zh active Pending
- 2005-03-17 JP JP2008501337A patent/JP2008533107A/ja not_active Ceased
- 2005-03-17 DK DK05728461T patent/DK1891961T3/da active
- 2005-03-17 US US11/908,697 patent/US7820637B2/en not_active Expired - Fee Related
- 2005-03-17 AT AT05728461T patent/ATE442854T1/de active
- 2005-03-17 WO PCT/ES2005/000139 patent/WO2006097547A1/es active Application Filing
- 2005-03-17 BR BRPI0520129-2A patent/BRPI0520129A2/pt not_active IP Right Cessation
-
2009
- 2009-12-02 CY CY20091101268T patent/CY1109539T1/el unknown
- 2009-12-04 HR HR20090646T patent/HRP20090646T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RS51122B (sr) | 2010-10-31 |
| SI1891961T1 (sl) | 2010-01-29 |
| DK1891961T3 (da) | 2009-12-21 |
| MX2007011327A (es) | 2008-01-28 |
| US7820637B2 (en) | 2010-10-26 |
| AU2005329287B2 (en) | 2011-01-27 |
| EP1891961A1 (en) | 2008-02-27 |
| EP1891961B1 (en) | 2009-09-16 |
| DE602005016729D1 (de) | 2009-10-29 |
| ES2334924T3 (es) | 2010-03-17 |
| AU2005329287A1 (en) | 2006-09-21 |
| PT1891961E (pt) | 2009-12-17 |
| ATE442854T1 (de) | 2009-10-15 |
| PL1891961T3 (pl) | 2010-02-26 |
| CY1109539T1 (el) | 2014-08-13 |
| US20090042831A1 (en) | 2009-02-12 |
| JP2008533107A (ja) | 2008-08-21 |
| CA2601557A1 (en) | 2006-09-21 |
| BRPI0520129A2 (pt) | 2009-04-28 |
| CN101141970A (zh) | 2008-03-12 |
| WO2006097547A1 (es) | 2006-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20090646T1 (hr) | Uporaba 5'-metiltioadenozina (mta) kod prevencije i/ili liječenja autoimunih bolesti i/ili odbacivanje transplantata | |
| ES2659205T3 (es) | Uso de 3-(5-amino-2-metil-4-oxoquinazolin-3(4H)-il)piperidin-2,6-diona en el tratamiento de enfermedades inflamatorias y relacionadas con el sistema inmune | |
| RU2010113964A (ru) | Применение соматостатина-14 в качестве терапевтического средства | |
| RU2010114018A (ru) | Применение пептид тимозина бета 4 индивидуально или в сочетании с цекропином а в качестве терапевтического средства | |
| SG169233A1 (en) | Pharmaceutical compositions comprising apomorphine for pulmonary inhalation | |
| DK0911033T3 (da) | Anvendelse af konsensusinterferon til reduktion af bivirkningerne af interferonbehandling i viral hepatitis | |
| HRP20040752B1 (hr) | Superfina formulacija formoterola | |
| WO2009039964A3 (en) | Use of glucagon-like peptide as a therapeutic agent | |
| EA200602016A1 (ru) | ПОРОШКОВЫЕ КОМПОЗИЦИИ ДЛЯ ИНГАЛЯЦИИ, СОДЕРЖАЩИЕ ЭНАНТИОМЕРНОЧИСТЫЕ β-АГОНИСТЫ | |
| RU2010108222A (ru) | Связывающие sdf-1 нуклеиновые кислоты и их применение | |
| WO2008022189A3 (en) | Administration of high potency platinum compound formulations by inhalation | |
| NZ578928A (en) | Methods to increase mobility of hematopoietic stem cells by use of a lipopeptide compound and treatment of associated diseases | |
| NO20054767L (no) | Sammensetninger omfattende apomorfin for inhalering i lunge | |
| DE68901153D1 (de) | Derivate von purin, verfahren zu ihrer herstellung und pharmazeutische zubereitung. | |
| MX2021014774A (es) | Formulaciones de liberacion modificada y usos de las mismas. | |
| Noori et al. | Effect of family-centered empowerment model on quality of life in patients with hypertension | |
| WO2009040085A3 (en) | Use of exendin-4 and optionally salusin-alpha as therapeutic agent(s) | |
| EA200971073A1 (ru) | Применение ранолазина при повышенном уровне натрийуретического пептида мозгового типа | |
| DE60115432D1 (de) | Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen | |
| AR012723A1 (es) | Derivados triptolidos utiles en el tratamiento de enfermedades autoinmunes y usos en la fabricacion de medicamentos | |
| Swart et al. | Changing winds in refractory autoimmune disease in children: clearing the road for tolerance with cellular therapies | |
| DK1289535T3 (da) | Apoptotiske enheder til anvendelse ved behandling af neurodegenerative og andre neurologiske sygdomme | |
| RU2010114005A (ru) | Применение сочетания пептидов тимозина бета4 и индуцирующего дельта-сон пептида в качестве терапевтического средства | |
| de Jong et al. | Local anesthetics: Injection route alters relative toxicity of bupivacaine | |
| Hejtmancik et al. | Symmetrical peripheral gangrene complicating pulmonary embolism |